Abstract: P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [3H]glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells, and to treat various conditions involving leukocyte binding via P-selectin glycoprotein ligand.

Abstract: A new class of synthetic glycosulfopeptides (GSPs) which have one or more sulfated tyrosine residues and a glycan linked to the peptide, the glycan preferably including a sialyl Lewisx group or a sialyl Lewisa group. In a preferred version the GSPs have an O-glycan comprising a &bgr;1,6 linkage to a GalNAc. The present invention further contemplates in vitro methods of the synthesis of these GSPs without the use of the cells and methods of their use in vivo as powerful anti-inflammatory antithrombotic, or anti-metastatic compounds. The invention also contemplates a method of synthesizing oligosaccharides by cleaving the glycan from the GSP.

Abstract: Compounds, compositions and methods for treating conditions characterized by leukocyte rolling are described. The compounds contain glycosulfopeptide structures comprising sulfated tyrosines and sialyated, fucosylated N-acetyllactosamino glycans. The glycosulfopeptides may be conjugated or complexed to other compounds for enhancing serum half-life or for controlled release, for example. Examples of conditions treated include inflammation, ischemia-reperfusion injury, rheumatoid arthritis, atherosclerosis, leukocyte-mediated lung injury, restenosis, and thrombosis.

Abstract: A new class of synthetic glycosulfopeptides (GSPs) which have one or more sulfated tyrosine residues and a glycan linked to the peptide, the glycan preferably including a sialyl Lewisx group or a sialyl Lewisa group. In a preferred version the GSPs have an O-glycan comprising a &bgr;1,6 linkage to a GalNAc. The present invention further contemplates in vitro methods of the synthesis of these GSPs without the use of the cells and methods of their use in vivo as powerful anti-inflammatory antithrombotic, or anti-metastatic compounds. The invention also contemplates a method of synthesizing oligosaccharides by cleaving the glycan from the GSP.

Abstract: Compounds, compositions and methods for treating conditions characterized by leukocyte rolling are described. The compounds contain glycosulfopeptide structures comprising sulfated tyrosines and sialyated, fucosylated N-acetyllactosamino glycans. The glycosulfopeptides may be conjugated or complexed to other compounds for enhancing serum half-life or for controlled release, for example. Examples of conditions treated include inflammation, ischemia-reperfusion injury, rheumatoid arthritis, atherosclerosis, leukocyte-mediated lung injury, restenosis, and thrombosis.

Abstract: A new class of synthetic glycosulfopeptides (GSPs) which have one or more sulfated tyrosine residues and a glycan linked to the peptide, the glycan preferably including a sialyl Lewisx group or a sialyl Lewisa group. In a preferred version the GSPs have an O-glycan comprising a &bgr;1,6 linkage to a GalNAc. The present invention further contemplates in vitro methods of the synthesis of these GSPs without the use of the cells and methods of their use in vivo as powerful anti-inflammatory antithrombotic, or anti-metastatic compounds. The invention also contemplates a method of synthesizing oligosaccharides by cleaving the glycan from the GSP.

Abstract: P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [3H]glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells, and to treat various conditions involving leukocyte binding via P-selectin glycoprotein ligand.

Abstract: A new class of synthetic glycosulfopeptides (GSPs) which have one or more sulfated tyrosine residues and a glycan linked to the peptide, the glycan preferably including a sialyl Lewisx group or a sialyl Lewisa group. In a preferred version the GSPs have an O-glycan comprising a &bgr;1, 6 linkage to a GalNAc. The present invention further contemplates in vitro methods of the synthesis of these GSPs without the use of the cells and methods of their use in vivo as powerful anti-inflammatory antithrombotic, or anti-metastatic compounds. The invention also contemplates a method of synthesizing oligosaccharides by cleaving the glycan from the GSP.

Abstract: Core 1 &bgr;3-galactosyl transferases and nucleic acids encoding the core 1 &bgr;3-galactosyl transferases are described. The enzymes and the nucleic acids encoding said enzymes have been identified in human, rat, mouse D. melanogaster and C. elegans. The polypeptides exhibit a wide range of homologies. The polynucleotides can be used to transform or transfect host cells for producing substantially pure forms of the enzyme, or for use in an expression system for post-translational core 1 O-linked glycosylation of proteins or peptides produced within the expression system. The enzymes can be used to galactosylate, via a &bgr;3-linkage, an N-acetylgalactosamine linked to a serine, threonine or other 0-linking amino acid on peptides or proteins requiring O-linked glycosylation.

Abstract: P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [3H]glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells.

Abstract: Species of Schistosoma, such as Schistosoma mansoni, S. japonicum and S. haematobium, which infect humans and animals, synthesize the Lewisx (Lex), lacdiNAc (LDN) and fucosylated LDN (LDNF) carbohydrate antigens. Parasitic helminths other than schistosomes, such as Dirofilaria immitis (responsible for heartworm), Fasciola hepatica (a liver fluke) and Haemonchus contortus (intestinal fluke) also synthesize the LDN and LDNF antigens, but they do not synthesize, or synthesize only undetectable amounts of, Lex antigen. The differential detection and abundance of the Lex, LDN and LDNF antigens in sera and other bodily fluids of individuals is diagnostic of the presence of active and/or previous infections from schistosomes and other parasitic helminths. The present invention is directed to methods of differential detection and diagnosis of parasitic helminth infections, and kits for use in such methods.

Abstract: Core 1 &bgr;3-galactosyl transferases and nucleic acids encoding the core 1 &bgr;3-galactosyl transferases are described. The enzymes and the nucleic acids encoding said enzymes have been identified in human, rat, mouse D. melanogaster and C. elegans. The polypeptides exhibit a wide range of homologies. The polynucleotides can be used to transform or transfect host cells for producing substantially pure forms of the enzyme, or for use in an expression system for post-translational core 1 O-linked glycosylation of proteins or peptides produced within the expression system. The enzymes can be used to galactosylate, via a &bgr;3-linkage, an N-acetylgalactosamine linked to a serine, threonine or other O-linking amino acid on peptides or proteins requiring O-linked glycosylation.

Abstract: This invention is biological in nature and relates to the synthesis, structure and biological activities of novel &agr;-1,2 and &agr;-1,3 fucosyltransferases from Caenorhabditis elegans (“C. elegans”). The present invention also contemplates a transgenic non-human eukaryotic mammal whose germ cells and somatic cells incorporate cDNA sequences encoding one or more of the novel &agr;-1,2 and &agr;-1,3 fucosyltransferases from C. elegans, introduced into the non-human eukaryotic mammal, or an ancestor of the non-human eukaryotic mammal, at an embyonic stage.

Abstract: P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [3H]glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells.

Abstract: A new class of synthetic glycosulfopeptides (GSPs) which have one or more sulfated tyrosine residues and a glycan linked to the peptide, the glycan preferably including a sialyl Lewisx group or a sialyl Lewisa group. In a preferred version the GSPs have an O-glycan comprising a &bgr;1,6 linkage to a GalNAc. The present invention further contemplates in vitro methods of the synthesis of these GSPs without the use of the cells and methods of their use in vivo as powerful anti-inflammatory antithrombotic, or anti-metastatic compounds. The invention also contemplates a method of synthesizing oligosaccharides by cleaving the glycan from the GSP.

Abstract: A new class of synthetic glycosulfopeptides (GSPs) which have one or more sulfated tyrosine residues and a glycan linked to the peptide, the glycan preferably including a sialyl Lewisx group or a sialyl Lewisa group. In a preferred version the GSPs have an O-glycan comprising a &bgr;1,6 linkage to a GalNAc. The present invention further contemplates in vitro methods of the synthesis of these GSPs without the use of the cells and methods of their use in vivo as powerful anti-inflammatory antithrombotic, or anti-metastatic compounds. The invention also contemplates a method of synthesizing oligosaccharides by cleaving the glycan from the GSP.

Abstract: P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [3H]glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells.

Abstract: Species of schistosoma , such as schistosoma mansoni, S. japonicum and S. haematobium, which infect humans and animals, synthesize the Lewisx (Lex), lacdiNAc (LDN) and fucosylated LDN (LDNF) carbohydrate antigens. Parasitic helminths other than schistosomes, such as Dirofilaria immitis (responsible for heartworm), Fasciola hepatica (a liver fluke) and Haemonchus contortus (intestinal fluke) also synthesize the LDN and LDNF antigens, but they do not synthesize, or synthesize only undetectable amounts of, Lex antigen. The differential detection and abundance of the Lex, LDN and LDNF antigens in sera and other bodily fluids of individuals is diagnostic of the presence of active and/or previous infections from schistosomes and other parasitic helminths. The present invention is directed to methods of differential detection and diagnosis of parasitic helminth infections, and kits for use in such methods.

Abstract: Methods for treating and modulating an inflammatory response using compositions containing a primarily monomeric or primarily dimeric form of galectin-1. The dimeric form stimulates apoptosis of activated neutrophils while the monomeric form inhibits apoptosis of activated neutrophils. Methods of screening for compounds which have galectin-1-like functions are also identified.

Abstract: The subject invention relates to methods of producing non-human transgenic mammals which produce various oligosaccharides and glycoconjugates in their milk. Additionally, the subject invention relates to the mammals themselves, the milk which they produce, compositions comprising the milk, fractions of the milk, and the purified oligosaccharides, as well as glyconjugates, present in the milk.